Захворюваність на COVID-19 та її вплив на смертність у хворих з легеневою артеріальною гіпертензією та хронічною тромбоемболічною легеневою гіпертензією

Abstract

The aim – the COVID-19 pandemic influenced seriously on people life in all of the world, including patients with such hard-chronic diseases like pulmonary hypertensions. The aim of our study was to evaluate the COVID-19 morbidity and its influence on mortality during the first 13 pandemic months in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Materials and methods. We provided the retrospective analysis of the patient data which were included in the center register before 31 March 2021. The evaluation of COVID-19 morbidity and mortality rate was done for the period between 01 March 2020 and 31 March 2021 (the period without active vaccination in Ukraine). The information about virus disease had to be confirmed by source documents. Results and discussion. Till 31 March 2021 the data of 494 patients with PAH/CTEPH were included in the register. 75 (15.2 %) patients died. During the follow-up period 44 patients suffered from COVID-19 (10.2 % among all (n=433) who were alive at 01 March 2020 or included in register after 01 March 2020). The most patients (91 %) with COVID-19 had the pneumonia, but only 9 (20.5 %) were hospitalized and 4 (9.1 %) were moved to the intensive care unit and died. In general PAH/CTEPH cohort the mortality rate was 2.9 % during the first 13 months of the pandemic. It did not significant differ with mortality rates in previous years, except 2015 year when the mortality rate was 12.3 %.Conclusion. The COVID-19 mortality was higher in pulmonary hypertensive patients in comparison with general Ukrainian population. But COVID-19 pandemic did not influence significantly on mortality rate in general PAH/CTEPH cohort during the first 13 pandemic months.